Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
about
Advancing regulatory science, advancing regulatory practice.Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for PsychopharmacologyDoes technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support framework.Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPDBenefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancerNumber needed to treat (NNT) in clinical literature: an appraisal.Perspectives on benefit-risk decision-making in vaccinology: Conference report.Adverse drug reactions in neonates: could we be documenting more?Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities.Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit-Risk Assessment of Medicines.Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.Literature review of visual representation of the results of benefit-risk assessments of medicinal products.Mesh in POP surgery should be based on the risk of the procedure, not the risk of recurrence.Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis.Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis.Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.Recommendations for benefit-risk assessment methodologies and visual representations.Risk Perceptions in Diabetic Patients Who Have Experienced Adverse Events: Implications for Patient Involvement in Regulatory Decisions.[Benefits of large healthcare databases for drug risk research].Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing among Statins in Primary Prevention.Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.Methodology for computing the burden of disease of adverse events following immunization.Benefit-Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project.Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis.Beyond the Label: Steering the Focus Toward Safe and Effective Prescribing.Assessing the Benefit-Risk Profile for Pediatric Implantable Auditory Prostheses.
P2860
Q33834239-6B394763-47A8-40D8-9D55-ED2D11A2EC3AQ34676317-5F565D8A-F46B-46C5-94A2-308A28A1A1FAQ35521438-473CCD65-5ED6-421E-BB5E-7DA9DE97A140Q35681671-1D02844E-222B-4403-AD48-2F5ED55B5FE8Q35794066-9C9A6F3E-EE69-4E71-A76F-1AEA825F5CC0Q36389996-DC4A2971-4684-4775-A81B-C184171450F2Q37130178-52D29855-A465-4642-9C61-11A414EBF685Q38250020-231EC7AE-EF20-4B56-88A1-BAB1B2A3FD74Q38284222-B0BCED8A-B12C-4FCE-8174-2A6C3BAE3AF5Q38485343-F822DD6A-9FC8-4EC9-8F0B-6883D19F7B0FQ38583668-9144E6E8-238D-48D3-B39A-A5CA30D8CD63Q38587979-D3B75114-0AA4-4FC1-A078-4BAA103BBDCCQ38621586-1EA0F023-23B6-41D6-A504-D6F5BD94BE25Q38720807-739ED0BB-E903-4F79-AEBC-600F52EEE06CQ38917477-0FEEE11D-157B-4AA4-86C9-4EAF3BCB1FD2Q38931021-1152EE2F-2067-4D02-8B55-0A6AAC431A6BQ39550978-7A615B4F-9079-4867-86D3-A443DB368E40Q40072719-70D56A7A-563F-45D8-9E9C-455E9C1D7C3EQ41204304-03B034C3-B5C4-4CFD-B72F-AB6BD472159FQ41656205-405DE4FD-ED20-4EF2-AEA8-B535A466DF2BQ41730760-7ABE169A-51DB-4725-8054-9AF35CD74CDAQ43762811-0B57C88E-6772-4CCD-A9CA-3BA4DFFED442Q51556405-DD61F677-E7F6-4AD0-A934-D67C6AFFEF0FQ52628777-E13D172D-C256-4567-A3F6-9689C6622DA5Q52673841-B9A8ADD7-7727-4A27-8000-04D7C47F8C51Q55224150-54869214-4424-4644-87BF-7628BD9207D9Q55365753-721DAB80-7E93-4E7C-AF2D-F469B1B060E6
P2860
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Balancing benefit and risk of ...... on of available methodologies.
@en
type
label
Balancing benefit and risk of ...... on of available methodologies.
@en
prefLabel
Balancing benefit and risk of ...... on of available methodologies.
@en
P2093
P2860
P50
P356
P1476
Balancing benefit and risk of ...... on of available methodologies.
@en
P2093
Alain Micaleff
Davide Luciani
George Quartey
Georgy Genov
IMI-PROTECT benefit-risk participants
Ian Hirsch
Isabelle Stoeckert
Kimberley S Hockley
Lawrence D Phillips
P2860
P304
P356
10.1002/PDS.3636
P577
2014-05-13T00:00:00Z